Lynx Raises $11.1 Million in Private Financing | GenomeWeb

NEW YORK, May 24 – Lynx Therapeutics said Thursday it had received a cash injection of $11.1 million in a private placement from a group of seven unnamed investors led by HBK Master Fund.

The new funds will help to shore up the companies dwindling resources as it continues developing its products and building its business. As of March 31, 2001, Lynx had $11.9 million in cash and cash equivalents.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.